Status:
ACTIVE_NOT_RECRUITING
Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin)
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Low or Intermediate Risk Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The integration of magnetic resonance imaging (MRI) in the treatment planning process for prostate cancer will reduce uncertainties in delineation of the prostate gland, and will enable delineation of...
Detailed Description
Advances in medical imaging, and their integration in the treatment planning and daily guidance of radiotherapy, stand to improve the therapeutic ratio. Improved imaging can reduce uncertainties by 1)...
Eligibility Criteria
Inclusion
- Low or intermediate risk localized prostate cancer:
- Gleason score ≤ 7
- PSA \<20
- Stage T2a or less (Stage 2 only)
- \<50% of biopsy cores involved with tumor (Stage 2 only)
Exclusion
- History of hip replacement
- Inflammatory bowel disease or collagen vascular disease
- Contraindication to fiducial marker placement
- Bleeding diathesis or anticoagulant therapy that cannot safely be ceased temporarily
- Severe adverse event with prior TRUS-guided prostate biopsy
- Patient refuses fiducial marker placement
- Contraindication to MRI
- Patient randomization in PROFIT Trial (Stage 2 only)
- Patients not prescribed 78Gy in 39 fractions to the prostate gland.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2027
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00890006
Start Date
September 1 2006
End Date
September 1 2027
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2M9